People
Laboratory members
Photo |
Who |
Research interests |
---|---|---|
Anna Wu
|
Akinyemi O. Oni-Orisan, PharmD, PhD Principal investigator X profile: @Akinyemi_OO Introduction: Brains and Braggadocio (audio, 50 minutes). Pronouns: he/him/his |
Clinical validation of pharmacogenetic associations for cardiovascular therapies. |
Elim Berhe Summer science research program student Pronouns: she/her/hers |
To (1) create safer and more effective treatment solutions for cancer and other life-threatening diseases, and (2) develop fresh pharmaceutical approaches that make use of drug discovery, targeted delivery systems, and personalized medicine techniques. | |
Chris Dimitropoulos, MS PharmD student Pronouns: he/him/his |
My research interests are using personalized medicine to improve health outcomes. Some fields I am interested in are Pharmacogenomics and Immunotherapy. |
|
Michael Douglas, MS Program manager X profile: @MDouglas_MS Pronouns: he/him/his |
Evaluating the equitable implementation of new technologies in precision medicine for cardiovascular disease, cancer, and pharmacogenomics. |
|
Boxuan "Jeffrey" Fan, BS Post-baccalaureate researcher Pronouns: he/him/his |
Exploring the application of data science, statistics, and computer science in the biomedical field, currently with an emphasis on pharmacogenomics. | |
Tanushree Haldar, PhD Data scientist Pronouns: she/her/hers |
Implementing statistical methods in both local and cloud computing platforms to analyze biomedical data with special emphasis on pharmacogenomics and genetic epidemiology. |
|
Mark Kvale, PhD Programmer/analyst Pronouns: he/him/his |
Using statistical genetics and machine learning techniques to analyze data, to infer results in large-scale genetic and genomic experiments, and to develop novel approaches to analysis. |
|
Neven Sarhan, PhD Postdoctoral fellow Pronouns: she/her/hers |
Applying statistical analysis to identify pharmacogenetic relationships related to cardiovascular therapies. |
|
Soha Shahidi, BS MS student in Health Data Science Pronouns: she/her/hers |
Applying machine learning techniques and statistical methods to better understand large genomic data sets for precision medicine. | |
Nanase Toda, BS PhD student in Pharmaceutical Sciences and Pharmacogenomics Pronouns: she/her/hers |
Developing and evaluating precision medicine tools to optimize the risk and benefit for therapies. | |
Imani Warren, BS PhD student in Pharmaceutical Sciences and Pharmacogenomics Pronouns: she/her/hers |
Evaluation of genetic ancestry versus social factors on race/ethnicity-based drug efficacy, safety, and drug response differences. |
Alumni
Photo | Name, Role, Years | Project | Now | |
---|---|---|---|---|
Oluwaseun "Seun" Odusan, BS Post-baccalaureate researcher 2023-2024 |
Statin-induced type 2 diabetes. | Senior patient coordinator, Weill Cornell Medical | ||
Joseph Harmon, BS Research Associate 2022-2023 Undergraduate Research Assistant 2019-2020 |
PlacEbo-controlled, Randomized, patient-Selected Outcomes N-of-1 triaL (PERSONAL-pilot): alpha-blockers for lower urinary tract symptoms | PhD student, Scripps Research. | ||
Janille Miranda, PharmD Intensive Research Project PharmD student 2021–2023 |
Candidate genetic variants of statin-induced myotoxicity. | PGY-1 ambulatory care pharmacy resident, Stanford University. | ||
Mari Cayabyab, PharmD Clinical Pharmacology and Therapeutics (CPT) postdoctoral fellow 2020–2022 |
Coronary heart disease polygenic risk score and secondary prevention of myocardial infarction. Abstract/Award: Cayabyab et al. Clin Pharmacol Ther. 2022;111: S63. Jason Morrow Trainee Award winner (2nd-best trainee abstract at the conference). |
Clinical pharmacy specialist – pharmacogenomics, University of Pennsylvania. | ||
Siem Tsegay Summer Student Research Program (SSRP) undergraduate student 2022 |
Pilot study to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of tamsulosin deprescribing. | Undergraduate student, Macalester College. | ||
Brian Lu, PharmD Pharmacogenomics Discovery Project PharmD student 2019–2021 |
Effect of SLCO1B1 T521C on statin-related myotoxicity with use of lovastatin and atorvastatin. Publication: Lu et al. Clin Pharmacol Ther. 2021 Sep;110(3):733-740. PMID: 34114646. |
Clinical pharmacist, Stanford Health Care Tri-Valley | ||
Laura Sun, PharmD Pharmacogenomics Discovery Project PharmD student 2019–2021 |
Effect of SLCO1B1 T521C on statin-related myotoxicity with use of lovastatin and atorvastatin | Clinical pharmacist, Winship Emory Midtown | ||
Adeya Wyatt, BS Summer Research Project undergraduate student 2020 |
The impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on inflammatory biomarkers. | PhD student, Columbia University, Biomedical Engineering |